Yahoo
NYSE USD

Artivion, Inc. (AORT)

22.58 -0.86 (-3.67%)
At close: October 30 at 4:00:02 PM EDT
22.58 0.00 (0.00%)
After hours: October 30 at 4:01:06 PM EDT
Trade AORT on Coinbase

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Mr. James Patrick Mackin
Chairman, President & CEO 1.88M 1.23M 1967
Mr. Lance A. Berry CPA
EVP, COO, CFO & Treasurer 1.02M -- 1972
Ms. Jean F. Holloway Esq.
Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary 719.6k 1.21M 1957
Mr. John E. Davis
Senior VP & Chief Commercial Officer 723.07k 416.66k 1965
Ms. Amy D. Horton CPA
VP & Chief Accounting Officer 621.26k 118.2k 1970
Mr. Matthew A. Getz
VP of Human Resources & Chief Human Resources Officer -- -- 1969
Mr. Jason D. Asper
Senior VP and Chief Strategy & Digital Officer -- -- 1976
Mr. Andrew M. Green
Senior Vice President of Regulatory & Quality -- -- 1969
Dr. Simona Zannetti M.D.
Senior Vice President of Clinical Research & Chief Medical Officer -- -- --
Dr. Robert C. Thomson Ph.D.
Vice President of Research & Development -- -- 1971

Artivion, Inc.

1655 Roberts Boulevard NW
Kennesaw, GA 30144
United States
770 419 3355 https://artivion.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
1,800

Description

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Corporate Governance

Artivion, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 5, 2026 at 9:00 PM UTC

Artivion, Inc. Earnings Date

Recent Events

August 7, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

August 6, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 21, 2026 at 12:00 AM UTC

SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)

May 18, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 15, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 8, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 7, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 1, 2026 at 12:00 AM UTC

ARS: Annual Report to Shareholders

February 18, 2026 at 12:00 AM UTC

10-K: Periodic Financial Reports

February 12, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: